Mucosal and Systemic Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Determined by Severity of Primary Infection.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 101674533 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2379-5042 (Electronic) Linking ISSN: 23795042 NLM ISO Abbreviation: mSphere Subsets: MEDLINE
    • Publication Information:
      Original Publication: Washington, DC : American Society for Microbiology, [2015]-
    • Subject Terms:
      SARS-CoV-2* ; COVID-19*/prevention & control; Humans ; Reinfection ; Vaccination ; Antibodies, Viral ; COVID-19 Vaccines ; Immunoglobulin A ; Immunoglobulin G
    • Abstract:
      With much of the world infected with or vaccinated against severe acute respiratory syndrome coronavirus 2 (commonly abbreviated SARS-CoV-2; abbreviated here SARS2), understanding the immune responses to the SARS2 spike (S) protein in different situations is crucial to controlling the pandemic. We studied the clinical, systemic, mucosal, and cellular responses to two doses of SARS2 mRNA vaccines in 62 individuals with and without prior SARS2 infection that were divided into three groups based on antibody serostatus prior to vaccination and/or degree of disease symptoms among those with prior SARS2 infection: antibody negative (naive), low symptomatic, and symptomatic. Antibody negative were subjects who were antibody negative (i.e., those with no prior infection). Low symptomatic subjects were those who were antibody negative and had minimal or no symptoms at time of SARS2 infection. Symptomatic subjects were those who were antibody positive and symptomatic at time of SARS2 infection. All three groups were then studied when they received their SARS2 mRNA vaccines. In the previously SARS2-infected (based on antibody test) low symptomatic and symptomatic groups, reactogenic symptoms related to a recall response were elicited after the first vaccination. Anti-S trimer IgA and IgG titers, and neutralizing antibody titers, peaked after the 1st vaccination in the previously SARS2-infected groups and were significantly higher than for the SARS2 antibody-negative group in the plasma and nasal samples at most time points. Nasal and plasma IgA antibody responses were significantly higher in the low symptomatic group than in the symptomatic group at most time points. After the first vaccination, differences in cellular immunity were not evident between groups, but the activation-induced cell marker (AIM + ) CD4 + cell response correlated with durability of IgG humoral immunity against the SARS2 S protein. In those SARS2-infected subjects, severity of infection dictated plasma and nasal IgA responses in primary infection as well as response to vaccination (peak responses and durability), which could have implications for continued protection against reinfection. Lingering differences between the SARS2-infected and SARS2-naive up to 10 months postvaccination could explain the decreased reinfection rates in the SARS2-infected vaccinees recently reported and suggests that additional strategies (such as boosting of the SARS2-naive vaccinees) are needed to narrow the differences observed between these groups. IMPORTANCE This study on SARS2 vaccination in those with and without previous exposure to the virus demonstrates that severity of infection dictates IgA responses in primary infection as well as response to vaccination (peak responses and durability), which could have implications for continued protection against reinfection.
    • References:
      J Hyg (Lond). 1985 Aug;95(1):173-89. (PMID: 2991366)
      Science. 2021 Oct 08;374(6564):eabh1823. (PMID: 34465633)
      JAMA. 2021 Apr 13;325(14):1467-1469. (PMID: 33646292)
      Euro Surveill. 2021 Feb;26(6):. (PMID: 33573712)
      Sci Immunol. 2021 Apr 15;6(58):. (PMID: 33858945)
      EMBO Mol Med. 2022 May 9;14(5):e15326. (PMID: 35393790)
      Nat Med. 2021 Nov;27(11):2032-2040. (PMID: 34588689)
      N Engl J Med. 2021 Dec 9;385(24):e85. (PMID: 34706170)
      Nature. 2022 Jan;601(7891):110-117. (PMID: 34758478)
      MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166. (PMID: 34437519)
      Lancet. 2021 Oct 16;398(10309):1407-1416. (PMID: 34619098)
      PLoS One. 2020 Nov 2;15(11):e0237828. (PMID: 33137138)
      Lancet. 2021 Mar 20;397(10279):1057-1058. (PMID: 33640038)
      Cell. 2020 Jun 25;181(7):1489-1501.e15. (PMID: 32473127)
      Mucosal Immunol. 2022 May;15(5):799-808. (PMID: 35468942)
      Nat Med. 2021 Dec;27(12):2127-2135. (PMID: 34650248)
      J Clin Invest. 2021 Jun 15;131(12):. (PMID: 33956667)
      Nat Med. 2021 Jun;27(6):981-984. (PMID: 33795870)
      Eur J Immunol. 2022 May;52(5):800-809. (PMID: 35128644)
      N Engl J Med. 2021 Dec 9;385(24):e84. (PMID: 34614326)
      J Immunol. 2016 Aug 1;197(3):983-93. (PMID: 27342848)
      J Infect Dis. 2020 Nov 13;222(12):1974-1984. (PMID: 32910175)
      Sci Transl Med. 2021 Jan 20;13(577):. (PMID: 33288661)
      MMWR Morb Mortal Wkly Rep. 2021 Aug 13;70(32):1081-1083. (PMID: 34383732)
      Science. 2021 Oct 22;374(6566):eabj9853. (PMID: 34519540)
      N Engl J Med. 2021 Nov 4;385(19):1761-1773. (PMID: 34525277)
      BMC Med. 2021 Jul 26;19(1):169. (PMID: 34304742)
      J Clin Microbiol. 2021 Apr 20;59(5):. (PMID: 33602698)
      Sci Rep. 2021 Dec 27;11(1):24448. (PMID: 34961780)
      Mucosal Immunol. 2011 Nov;4(6):598-602. (PMID: 21956244)
      Science. 2020 Oct 2;370(6512):89-94. (PMID: 32753554)
      J Immunol. 2016 Aug 1;197(3):994-1002. (PMID: 27335502)
      Nat Med. 2021 Jul;27(7):1205-1211. (PMID: 34002089)
      N Engl J Med. 2020 Dec 10;383(24):2320-2332. (PMID: 32877576)
      Cell. 2022 Jul 7;185(14):2434-2451.e17. (PMID: 35764089)
      Clin Biochem. 2021 Apr;90:23-27. (PMID: 33472036)
      EBioMedicine. 2022 Jan;75:103788. (PMID: 34954658)
      N Engl J Med. 2021 Apr 8;384(14):1372-1374. (PMID: 33691060)
      J Clin Invest. 2020 Nov 2;130(11):6141-6150. (PMID: 32764200)
      Cell Rep Med. 2021 Jul 20;2(7):100329. (PMID: 34151306)
      Immunity. 2019 Jan 15;50(1):241-252.e6. (PMID: 30552025)
      J Exp Med. 2002 Aug 5;196(3):303-10. (PMID: 12163559)
      Science. 2021 Mar 25;:. (PMID: 33766944)
      Nature. 2021 Jul;595(7867):426-431. (PMID: 34126625)
      Nature. 2021 Dec;600(7889):530-535. (PMID: 34670266)
      Viruses. 2020 Dec 04;12(12):. (PMID: 33291713)
    • Grant Information:
      I01 BX005469 United States BX BLRD VA; R01 AI147870 United States AI NIAID NIH HHS; T32 AI007524 United States AI NIAID NIH HHS
    • Contributed Indexing:
      Keywords: IgA; IgG; SARS-CoV-2; mucosal immunity; systemic response; vaccination
    • Accession Number:
      0 (Antibodies, Viral)
      0 (COVID-19 Vaccines)
      0 (Immunoglobulin A)
      0 (Immunoglobulin G)
    • Publication Date:
      Date Created: 20221102 Date Completed: 20221223 Latest Revision: 20231213
    • Publication Date:
      20231215
    • Accession Number:
      PMC9769618
    • Accession Number:
      10.1128/msphere.00279-22
    • Accession Number:
      36321826